{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:00:06Z","timestamp":1790830806871,"version":"4.1.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the predictive value of glycated CD59 (gCD59) during mid-pregnancy for adverse pregnancy outcomes, specifically macrosomia and large for gestational age (LGA), in a prospective cohort of pregnant women undergoing oral glucose tolerance testing (OGTT), with adjustment for gestational diabetes mellitus (GDM) status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 672 pregnant women who attended prenatal visits at the Affiliated Suqian Hospital of Xuzhou Medical University from January 2022 to July 2023 were enrolled, and baseline data were collected via the Zhendings Maternal and Child Health System. At 24\u201328 weeks of gestation, an oral glucose tolerance test (OGTT) was performed. Based on the results, participants were divided into a GDM group and a normal glucose tolerance (NGT) group for descriptive comparisons; for all predictive analyses, GDM status was included as a covariate in multivariable models. Concurrently, gCD59 levels were measured using the ELISA method. The pregnant women were followed up until after delivery, and data on delivery-related information and pregnancy outcomes were collected. Differences in pregnancy outcomes between the two groups were compared. Logistic regression analysis was used to identify risk factors for adverse pregnancy outcomes, and the predictive value of gCD59 levels for adverse pregnancy outcomes was assessed using ROC curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Macrosomia and Large for Gestational Age (LGA) were the two most common adverse pregnancy outcomes. Compared with the NGT group, the incidence of macrosomia and LGA was significantly higher in the GDM group (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05). Compared with the NGT group, gCD59 levels were significantly higher in the GDM group (1.49 (0.90, 2.33) vs. 0.87 (0.39, 1.62), P &amp;lt; 0.001). Logistic regression analysis indicated that gCD59 was an independent risk factor for macrosomia and LGA, and the incidence of macrosomia and LGA increased with rising gCD59 levels. In predictive modeling, the addition of gCD59 to traditional risk factors improved the AUC for macrosomia from 0.770 (95% CI: 0.679\u20130.833) to 0.864 (95% CI: 0.823\u20130.904) (DeLong\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.046); for LGA, the AUC improved from 0.723 (95% CI: 0.663\u20130.782) to 0.790 (95% CI: 0.737\u20130.843) (DeLong\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.103).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Macrosomia and LGA were the most common adverse pregnancy outcomes in the study cohort. gCD59 was identified as an independent risk factor for both macrosomia and LGA. In predictive modeling, gCD59 demonstrated statistically significant incremental value for macrosomia (AUC: 0.770 vs. 0.864, DeLong\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.046), while for LGA the improvement showed a favorable trend but did not reach statistical significance (AUC: 0.723 vs. 0.790, DeLong\n                      <jats:italic>P<\/jats:italic>\n                      =\u00a00.103). These findings suggest that gCD59 may serve as a supplementary biomarker, particularly for risk stratification of macrosomia, with potential utility for identifying pregnancies at risk of excessive fetal growth.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1924289","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:45:18Z","timestamp":1790829918000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The predictive value of glycated CD59 for fetal overgrowth in second-trimester pregnant women"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiaofan","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Suqian Hospital Affiliated to Xuzhou Medical University","place":["Suqian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Suqian Hospital Affiliated to Xuzhou Medical University","place":["Suqian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Gang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Suqian Hospital Affiliated to Xuzhou Medical University","place":["Suqian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Dou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Suqian Clinical College of Xuzhou Medical University","place":["Suqian, China"]},{"name":"Department of Endocrinology, Jiangsu Province Suqian Hospital","place":["Suqian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Suqian Hospital Affiliated to Xuzhou Medical University","place":["Suqian, China"]},{"name":"Department of Endocrinology, Nanjing Drum Tower Hospital Group Suqian Hospital","place":["Suqian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Suqian Clinical College of Xuzhou Medical University","place":["Suqian, China"]},{"name":"Department of Endocrinology, Jiangsu Province Suqian Hospital","place":["Suqian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.4063","article-title":"Diagnosis and management of prediabetes: a review","volume":"329","author":"Echouffo-Tcheugui","year":"2023","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S2213-8587(20)30161-3","article-title":"Gestational diabetes: opportunities for improving maternal and child health","volume":"8","author":"Saravanan","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.freeradbiomed.2023.10.014","article-title":"Longitudinal metabolomics integrated with machine learning identifies novel biomarkers of gestational diabetes mellitus","volume":"209","author":"Lu","year":"2023","journal-title":"Free Radic Biol Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"E999","DOI":"10.1210\/jc.2013-4232","article-title":"Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans","volume":"99","author":"Ghosh","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s0969-2126(00)00020-4","article-title":"Structure of a soluble, glycosylated form of the human complement regulatory protein CD59","volume":"2","author":"Fletcher","year":"1994","journal-title":"Structure"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110023","article-title":"The utility of first trimester plasma glycated CD59 (pGCD59) in predicting gestational diabetes mellitus: a prospective study of non-diabetic pregnant women in Ireland","volume":"190","author":"Bogdanet","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1374253","article-title":"Glycated CD59 is a potential biomarker for gestational diabetes mellitus","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70013","article-title":"Plasma glycated CD59 and gestational diabetes mellitus: a systematic review","volume":"7","author":"Asadi","year":"2024","journal-title":"Endocrinol Diabetes Metab"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.10.012","article-title":"Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy: a World Health Organization guideline","volume":"103","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23478","article-title":"A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes","volume":"88","author":"Ghosh","year":"2013","journal-title":"Am J Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac498","article-title":"The role of early pregnancy maternal pGCD59 levels in predicting neonatal hypoglycemia-subanalysis of the DALI study","volume":"107","author":"Bogdanet","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15121","article-title":"The utility of plasma glycated CD59 in predicting postpartum glucose intolerance: a prospective study of women diagnosed with GDM during a period of universal GDM screening","volume":"40","author":"Bogdanet","year":"2023","journal-title":"Diabetes Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067946","article-title":"Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis","volume":"377","author":"Ye","year":"2022","journal-title":"BMJ"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2023.08.011","article-title":"Gestational diabetes mellitus and adverse maternal and perinatal outcomes in twin and singleton pregnancies: a systematic review and meta-analysis","volume":"230","author":"Greco","year":"2024","journal-title":"Am J Obstet Gynecol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12884-023-05440-9","article-title":"Maternal circulating metabolic biomarkers and their prediction performance for gestational diabetes mellitus related macrosomia","volume":"23","author":"Yuan","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/srep17212","article-title":"The role, mechanism and potentially novel biomarker of microRNA-17-92 cluster in macrosomia","volume":"5","author":"Li","year":"2015","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2598","article-title":"Plasma glycated CD59, a novel biomarker for detection of pregnancy-induced glucose intolerance","volume":"40","author":"Ghosh","year":"2017","journal-title":"Diabetes Care"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa087","article-title":"Plasma glycated CD59 predicts early gestational diabetes and large for gestational age newborns","volume":"105","author":"Ma","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.53.10.2653","article-title":"Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes","volume":"53","author":"Qin","year":"2004","journal-title":"Diabetes"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.3.985","article-title":"Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells","volume":"179","author":"Benzaquen","year":"1994","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-022-01983-z","article-title":"The ability of pGCD59 to predict adverse pregnancy outcomes: a prospective study of non-diabetic pregnant women in Ireland","volume":"60","author":"Bogdanet","year":"2023","journal-title":"Acta Diabetol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1924289\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:45:22Z","timestamp":1790829922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1924289\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":21,"alternative-id":["10.3389\/fendo.2026.1924289"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1924289","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1924289"}}